Literature DB >> 21531945

JAK2V⁶¹⁷F/TET2 mutations: does the order matter?

Elodie Pronier, Cyril Quivoron, Olivier A Bernard, Jean-Luc Villeval.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21531945      PMCID： PMC3084907          DOI： 10.3324/haematol.2011.042846

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  24 in total

1.  Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.

Authors:  Sabina I Swierczek; Donghoon Yoon; Christine Bellanné-Chantelot; Soo Jin Kim; Cécile Saint-Martin; Francois Delhommeau; Albert Najman; Josef T Prchal
Journal:  Haematologica       Date:  2011-01-27       Impact factor: 9.941

2.  TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23).

Authors:  R B Lorsbach; J Moore; S Mathew; S C Raimondi; S T Mukatira; J R Downing
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

3.  Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells.

Authors:  Kian Peng Koh; Akiko Yabuuchi; Sridhar Rao; Yun Huang; Kerrianne Cunniff; Julie Nardone; Asta Laiho; Mamta Tahiliani; Cesar A Sommer; Gustavo Mostoslavsky; Riitta Lahesmaa; Stuart H Orkin; Scott J Rodig; George Q Daley; Anjana Rao
Journal:  Cell Stem Cell       Date:  2011-02-04       Impact factor: 24.633

4.  Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine.

Authors:  Chun-Xiao Song; Keith E Szulwach; Ye Fu; Qing Dai; Chengqi Yi; Xuekun Li; Yujing Li; Chih-Hsin Chen; Wen Zhang; Xing Jian; Jing Wang; Li Zhang; Timothy J Looney; Baichen Zhang; Lucy A Godley; Leslie M Hicks; Bruce T Lahn; Peng Jin; Chuan He
Journal:  Nat Biotechnol       Date:  2010-12-12       Impact factor: 54.908

5.  5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming.

Authors:  Mark Wossidlo; Toshinobu Nakamura; Konstantin Lepikhov; C Joana Marques; Valeri Zakhartchenko; Michele Boiani; Julia Arand; Toru Nakano; Wolf Reik; Jörn Walter
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

6.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

7.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

8.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

9.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

10.  Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.

Authors:  Franz X Schaub; Renate Looser; Sai Li; Hui Hao-Shen; Thomas Lehmann; Andre Tichelli; Radek C Skoda
Journal:  Blood       Date:  2010-01-08       Impact factor: 22.113
View more
  2 in total

Review 1.  Myeloid malignancies: mutations, models and management.

Authors:  Anne Murati; Mandy Brecqueville; Raynier Devillier; Marie-Joelle Mozziconacci; Véronique Gelsi-Boyer; Daniel Birnbaum
Journal:  BMC Cancer       Date:  2012-07-23       Impact factor: 4.430

2.  Inferring the temporal order of cancer gene mutations in individual tumor samples.

Authors:  Jun Guo; Hanliang Guo; Zhanyi Wang
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.